Update on the Diagnosis and Management of Neurocysticercosis

Springer Science and Business Media LLC - Tập 18 - Trang 1-8 - 2016
Camille M. Webb1, A. Clinton White1
1Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston, USA

Tóm tắt

Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.

Tài liệu tham khảo

Coyle CM, Mahanty S, Zunt JR, et al. Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis. 2012;6(5), e1500.

Garcia H, Coyle C, White Jr AC. Cysticercosis. In: Guerrant R, Walker D, Weller P, editors. Tropical Infectious Diseases, Principles, Pathogens and Practice. 3rd ed. Philadelphia: Elsevier-Saunders; 2011. p. 815–23.

Ndimubanzi PC, Carabin H, Budke CM, et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4(11), e870.

•• O’Keefe KA, Eberhard ML, Shafir SC, Wilkins P, Ash LR, Sorvillo FJ. Cysticercosis-related hospitalizations in the United States, 1998–2011. Am J Trop Med Hyg. 2015;92(2):354–9. This study independantly evaluated national databases of hospital discharges for Neurocysticercosis admissions in the United State. This document over 2,000 cases admitted to hospitals per year.

•• O’Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis. 2015;21(6):969–76. This study independantly evaluated national databases of hospital discharges for Neurocysticercosis admissions in the United State. This document over 2,000 cases admitted to hospitals per year.

Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol. 2014;13(12):1202–15.

García HH, Gonzalez AE, Rodriguez S, et al. Neurocysticercosis: unraveling the nature of the single cysticercal granuloma. Neurology. 2010;75(7):654–8.

Serpa JA, Graviss EA, Kass JS, White AC. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore). 2011;90(1):81–6.

Serpa JA, White Jr, AC. Neurocysticercosis in the United States. Pathog Glob Health. 2012;106(5):256–60.

Rajshekhar V, Chandy MJ. Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. Acta Neurol Scand. 1997;96(2):76–81.

Villarán MV, Montano SM, Gonzalvez G, et al. Epilepsy and neurocysticercosis: an incidence study in a Peruvian rural population. Neuroepidemiology. 2009;33(1):25–31.

Moyano LM, Saito M, Montano SM, et al. Neurocysticercosis as a cause of epilepsy and seizures in two community-based studies in a cysticercosis-endemic region in Peru. PLoS Negl Trop Dis. 2014;8(2), e2692.

Nash TE, Pretell EJ, Lescano AG, et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol. 2008;7(12):1099–105.

Rangel-Castilla L, Serpa J, Gopinath S, Graviss E, Diaz-Marchan P, White Jr, AC. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg. 2009;80(3):373–8.

Callacondo D, Garcia HH, Gonzales I, Escalante D, Nash TE, et al. High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis. Neurology. 2012;78(18):1394–400.

Cárdenas G, Guevara-Silva E, Romero F, et al. Spinal Taenia solium cysticercosis in Mexican and Indian patients: a comparison of 30-year experience in two neurological referral centers and review of literature. Eur Spine J. 2016;25(4):1073–81.

Rath S, Honavar SG, Naik M, et al. Orbital cysticercosis: clinical manifestations, diagnosis, management, and outcome. Ophthalmology. 2010;117(3):600–5. 5.e1.

Madigubba S, Vishwanath K, Reddy G, Vemuganti GK. Changing trends in ocular cysticercosis over two decades: an analysis of 118 surgically excised cysts. Indian J Med Microbiol. 2007;25(3):214–9.

Gonzales I, Miranda JJ, Rodriguez S, et al. Seizures, cysticercosis and rural-to-urban migration: the PERU MIGRANT study. Trop Med Int Health. 2015;20(4):546–52.

del la Garza Y, Graviss EA, Daver NG, et al. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg. 2005;73(4):766–70.

Del Brutto OH. Neurocysticercosis among international travelers to disease-endemic areas. J Travel Med. 2012;19(2):112–7.

Carrillo Mezo R, Lara García J, Arroyo M, Fleury A. Relevance of 3D magnetic resonance imaging sequences in diagnosing basal subarachnoid neurocysticercosis. Acta Trop. 2015;152:60–5.

Neyaz Z, Patwari SS, Paliwal VK. Role of FIESTA and SWAN sequences in diagnosis of intraventricular neurocysticercosis. Neurol India. 2012;60(6):646–7.

Mont’Alverne Filho FE, Machado Lo R, Lucato LT, Leite CC. The role of 3D volumetric MR sequences in diagnosing intraventricular neurocysticercosis: preliminar results. Arq Neuropsiquiatr. 2011;69(1):74–8.

Furrows S, McCroddan J, Bligh W, Chiodini P. Lack of specificity of a single positive 50-kDa band in the electroimmunotransfer blot (EITB) assay for cysticercosis. Clin Microbiol Infect. 2006;12(5):459–62.

Carod JF, Randrianarison M, Razafimahefa J, et al. Evaluation of the performance of 5 commercialized enzyme immunoassays for the detection of Taenia solium antibodies and for the diagnosis of neurocysticercosis. Diagn Microbiol Infect Dis. 2012;72(1):85–9.

Gabriël S, Blocher J, Dorny P, et al. Added value of antigen ELISA in the diagnosis of neurocysticercosis in resource poor settings. PLoS Negl Trop Dis. 2012;6(10), e1851.

Deckers N, Dorny P. Immunodiagnosis of Taenia solium taeniosis/cysticercosis. Trends Parasitol. 2010;26(3):137–44.

Gonzalez AE, Bustos JA, Garcia HH, et al. Successful antiparasitic treatment for cysticercosis is associated with a fast and marked reduction of circulating antigen levels in a naturally infected pig model. Am J Trop Med Hyg. 2015;93(6):1305–10.

Fleury A, Garcia E, Hernández M, et al. Neurocysticercosis: HP10 antigen detection is useful for the follow-up of the severe patients. PLoS Negl Trop Dis. 2013;7(3), e2096.

Gonzales I, Rivera JT, Garcia HH, Peru CWGI. Pathogenesis of Taenia solium taeniasis and cysticercosis. Parasite Immunol. 2016;38(3):136–46.

Nash TE, Mahanty S, Loeb JA, et al. Neurocysticercosis: a natural human model of epileptogenesis. Epilepsia. 2015;56(2):177–83.

Rajshekhar V, Jeyaseelan L. Seizure outcome in patients with a solitary cerebral cysticercus granuloma. Neurology. 2004;62(12):2236–40.

Sharma M, Singh T, Mathew A. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev. 2015;10, CD009027.

Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology. 2013;80(2):152–62.

Zhao BC, Jiang HY, Ma WY, et al. Albendazole and corticosteroids for the treatment of solitary cysticercus granuloma: a network meta-analysis. PLoS Negl Trop Dis. 2016;10(2), e0004418.

Singh G, Murthy JM. Solitary cysticercus granuloma-treatment with albendazole: what is the optimal duration? Neurol India. 2010;58(4):507–8.

Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004;350(3):249–58.

Carpio A, Kelvin E, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008;79(9):1050–5.

Romo ML, Wyka K, Carpio A, et al. The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. Trans R Soc Trop Med Hyg. 2015;109(11):738–46.

Garcia HH, Lescano AG, Lanchote VL, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol. 2011;72(1):77–84.

•• Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(8):687–95. This welll-designed randomized clinical trial demonstrated the efficacy of combination antiparasitic therapy in patients with multiple parenchymal cysticerci.

• Garcia HH, Lescano AG, Gonzales I, et al. Cysticidal efficacy of combined treatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis. 2016;62(11):1375–9. This study confirms the improved cysticidal activity of combination antiparasitic therapy.

• Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia. 2014;55(9):1452–9. This randomized trial demonstrated an improved clinical response when antiparasitic drugs were accompanied by higher doses of corticosteroids.

Bustos JA, García HH, Del Brutto OH. Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis. Expert Rev Neurother 2016: 1–7.

Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology. 2002;59(11):1730–4.

Nash TE, Bartelt LA, Korpe PS, Lopes B, Houpt ER. Calcified neurocysticercus, perilesional edema, and histologic inflammation. Am J Trop Med Hyg. 2014;90(2):318–21.

Fujita M, Mahanty S, Zoghbi SS, et al. PET reveals inflammation around calcified Taenia solium granulomas with perilesional edema. PLoS One. 2013;8(9), e74052.

Mejia R, Nash TE. Corticosteroid withdrawal precipitates perilesional edema around calcified Taenia solium cysts. Am J Trop Med Hyg. 2013;89(5):919–23.

Bianchin MM, Velasco TR, Wichert-Ana L, et al. Neuroimaging observations linking neurocysticercosis and mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Res. 2015;116:34–9.

Del Brutto OH, Salgado P, Lama J, et al. Calcified neurocysticercosis associates with hippocampal atrophy: a population-based study. Am J Trop Med Hyg. 2015;92(1):64–8.

Rathore C, Thomas B, Kesavadas C, Abraham M, Radhakrishnan K. Calcified neurocysticercosis lesions and antiepileptic drug-resistant epilepsy: a surgically remediable syndrome? Epilepsia. 2013;54(10):1815–22.

Proaño JV, Torres-Corzo J, Rodríguez-Della Vecchia R, Guizar-Sahagun G, Rangel-Castilla L. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst. 2009;25(11):1467–75.

Torres-Corzo J, Rodriguez-della Vecchia R, Rangel-Castilla L. Bruns syndrome caused by intraventricular neurocysticercosis treated using flexible endoscopy. J Neurosurg. 2006;104(5):746–8.

Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg. 1987;66(5):686–9.

Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001;345(12):879–85.

Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis. 2007;44(4):549–53.

•• Garcia HH, Gonzalez AE, Tsang VC, et al. Elimination of Taenia solium transmission in Northern Peru. N Engl J Med. 2016;374(24):2335–44. This study demonstrates the feasibility of elimination of Taenia solium transmission in a region in northern Peru using mass chemotherapy for human tapeworm carriers, mass chemotherapy of pigs, and vaccination of pigs.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 18

1-8

Thông tin tác giả